Jared Gollob - 01 Nov 2021 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Medical Officer
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
01 Nov 2021
Net transactions value
-$3,506,684
Form type
4
Filing time
02 Nov 2021, 18:45:15 UTC
Next filing
03 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $26,200 +20,000 +47% $1.31* 62,547 01 Nov 2021 Direct
transaction KYMR Common Stock Options Exercise $9,583 +4,607 +7.4% $2.08* 67,154 01 Nov 2021 Direct
transaction KYMR Common Stock Sale $446,142 -7,387 -11% $60.40 59,767 01 Nov 2021 Direct F1, F2
transaction KYMR Common Stock Sale $930,709 -15,134 -25% $61.50 44,633 01 Nov 2021 Direct F1, F3
transaction KYMR Common Stock Sale $991,946 -15,911 -36% $62.34 28,722 01 Nov 2021 Direct F1, F4
transaction KYMR Common Stock Sale $256,799 -4,065 -14% $63.17 24,657 01 Nov 2021 Direct F1, F5
transaction KYMR Common Stock Options Exercise $31,192 +14,996 +61% $2.08* 39,653 02 Nov 2021 Direct
transaction KYMR Common Stock Sale $535,442 -8,514 -21% $62.89 31,139 02 Nov 2021 Direct F1, F6
transaction KYMR Common Stock Sale $335,287 -5,280 -17% $63.50 25,859 02 Nov 2021 Direct F1, F7
transaction KYMR Common Stock Sale $77,333 -1,202 -4.6% $64.34 24,657 02 Nov 2021 Direct F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -20,000 -33% $0.000000 40,007 01 Nov 2021 Common Stock 20,000 $1.31 Direct F9
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -4,607 -3.3% $0.000000 133,808 01 Nov 2021 Common Stock 4,607 $2.08 Direct F10
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -14,996 -11% $0.000000 118,812 02 Nov 2021 Common Stock 14,996 $2.08 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.01 to $62.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.03 to $63.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.03 to $63.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.13 to $63.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.13 to $64.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F8 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.13 to $64.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F9 Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.
F10 The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.